Hitting bone during an intramuscular injection is physically possible, and it happens more often than most people realize. The risk depends on the injection site, needle length, the person’s body composition, and the angle of insertion. Researchers studying tissue thickness across different body types have found that in some individuals, especially those with low body fat or thin muscle layers, a standard-length needle can reach all the way to bone. Understanding when and why this happens matters for anyone giving or receiving injections.
Why Bone Contact Happens
An intramuscular injection is meant to deposit medication into the muscle layer beneath the skin and subcutaneous fat. A needle that is too long for the amount of tissue at the injection site can pass through the muscle entirely and strike the bone underneath. Whether this happens comes down to a straightforward measurement problem: the distance from the skin surface to bone varies dramatically from person to person.
In the deltoid, which is the most common site for vaccines, the total tissue depth from skin surface to the humerus (the upper arm bone) depends heavily on body fat and muscle mass. CT imaging of adults has shown that this depth ranges widely, with some thin individuals having less than 20 mm of tissue between skin and bone, while others have 40 mm or more. A standard 25 mm (one-inch) needle inserted at a 90-degree angle in a person with relatively little tissue over the deltoid can easily reach bone. An ultrasound study of elderly patients found that body mass index was strongly correlated with the thickness of the fat layer over the deltoid muscle. In males and females with a BMI under 35, a 25 mm needle was generally sufficient for intramuscular injection without overshooting, but the same study confirmed that the margin between reaching the muscle and reaching bone can be slim in leaner individuals.
Which Injection Sites Are Riskier
Not all injection sites carry the same risk of bone contact. The deltoid muscle in the upper arm sits over the humerus and is relatively thin compared to the gluteal muscles. The anterolateral thigh, commonly used for infants and toddlers, overlies the femur. Both of these sites have less tissue depth than the gluteal region in most adults.
Among the gluteal options, research comparing the dorsogluteal site (the traditional “upper outer buttock” area) and the ventrogluteal site (on the hip) found that the ventrogluteal site tends to be safer in terms of avoiding bone contact. A study examining intramuscular injection safety in older adults concluded that both gluteal sites had adequate tissue thickness, but the ventrogluteal site carried a lower risk of bone contact and a lower risk of the injection ending up in subcutaneous fat rather than muscle. This is one reason clinical guidelines have increasingly favored the ventrogluteal site over the dorsogluteal for many medications, though both remain in use.
At the dorsogluteal site, the sciatic nerve is an additional concern. An analysis of Supreme Court decisions in Turkey involving injection-induced sciatic nerve injuries found that gluteal injections accounted for 79% of cases, with nurses performing 60% of the injections involved in litigation. That study focused on nerve damage rather than bone contact, but it underscores the broader point that the dorsogluteal site has multiple layers of risk beyond just inadvertent bone strike.
How Body Composition Changes the Equation
Body mass index is the single strongest predictor of whether a given needle will reach muscle, fall short in subcutaneous fat, or overshoot into bone. But it works in both directions in ways that are not always intuitive.
In people with higher BMI, the main risk is actually the opposite of bone contact: the needle may not reach the muscle at all, depositing medication into the fat layer instead. A systematic review of variables affecting needle length choice for deltoid injections found that in every BMI category above 25, at least some individuals would need a needle longer than 25 mm to penetrate the deltoid muscle by a minimum of 5 mm. For people with a BMI over 35, particularly women, a 32 mm needle may be necessary.
In leaner individuals, the concern flips. With less subcutaneous fat padding the space between skin and bone, a standard needle has more penetration depth available than the tissue can absorb. A combined analysis of New Zealand data found that the BMI thresholds where needle length became critical differed between men and women: the cut-point above which a 25 mm needle would reach the muscle without overshooting was around 38 for men but only about 32 for women. Below these thresholds, shorter needles or adjusted techniques might be needed to avoid going too deep.
Sex matters independently of BMI, too. Women tend to carry more subcutaneous fat over the deltoid than men at the same BMI, which can actually be protective against bone contact but increases the chance of a subcutaneous deposit. Men at the same BMI tend to have thinner fat layers, which means the needle reaches muscle more easily but also passes through it faster toward bone. The tissue geometry is genuinely different between the sexes, even when the numbers on the scale are similar.
What Actually Happens If a Needle Hits Bone
A brief tap against the periosteum, the membrane covering bone, is painful but usually harmless. Most people who have hit bone during an injection describe a sharp, electric jolt of pain that resolves quickly once the needle is slightly withdrawn. In clinical practice, the needle is simply pulled back a few millimeters before injecting. No lasting damage occurs in the vast majority of these cases.
Serious complications from bone contact are rare but not unheard of. A published case report described an adolescent who developed osteomyelitis, a bone infection, after intramuscular vaccine administration. Imaging of her arm was suspicious for osteomyelitis, which was confirmed by incision, drainage, and bone biopsy. She required a six-week course of antibiotic therapy. The injury was attributed to overpenetration by the needle during the injection she had received the previous month. This is an extreme outcome, and the case report exists precisely because it is unusual enough to be worth documenting. But it illustrates that the consequences of bone contact are not always trivial, especially if bacteria are introduced to the periosteum or bone surface.
There is also a practical concern about medication delivery. If a needle strikes bone, the person administering the injection instinctively stops pushing or pulls back. This disruption can lead to partial injection into the wrong tissue layer, or medication leaking back through the needle track. Neither outcome is dangerous with most vaccines, but with certain medications where precise intramuscular delivery matters for absorption, it can affect how well the drug works.
Why Injection Depth Matters for How Drugs Work
The distinction between injecting into muscle versus fat is not just academic. Muscle tissue has a rich blood supply, which means drugs injected into it are absorbed relatively quickly and predictably. Subcutaneous fat has much less blood flow, and research has shown that this fat layer acts as a brake on absorption, particularly for lipophilic (fat-soluble) drugs. The subcutaneous adipose layer significantly slows absorption, with mean absorption times considerably longer when a drug ends up in fat rather than muscle.
Bone contact creates the opposite problem: the medication may pool against a hard surface rather than dispersing evenly through muscle fibers, and the sharp pain may cause the person receiving the injection to flinch or the administrator to adjust mid-injection, leading to uneven distribution. For vaccines, where the immune response depends on the medication reaching the right tissue, consistent intramuscular delivery is the goal. Studies on immunogenicity generally show that vaccines delivered intramuscularly produce the expected immune response, while those accidentally deposited in fat may produce a weaker or delayed response.
Needle Length Selection and Technique
Most of the risk of bone contact comes down to choosing the right needle for the person in front of you. The standard 25 mm (one-inch) needle works well for the majority of adults receiving deltoid injections, but it is not universally appropriate. For very lean individuals or those with minimal muscle mass, it can be too long. For larger individuals, it may be too short to reach the muscle at all.
An ultrasound study of early adolescents measured the depth of muscle and bone underlying the deltoid injection site. The researchers defined a “sufficiently long” needle as one at least equal to the skin-to-muscle depth plus 5 mm, ensuring the tip was firmly within the muscle. They defined “too long” as a needle that would reach or exceed the skin-to-bone depth. This framing captures the core challenge: there is a window of correct needle length for each person, and that window can be narrow.
Technique matters alongside needle length. Bunching (pinching up) the skin and underlying tissue before injecting is common practice, especially in children, but it changes the geometry. Research on COVID vaccine administration found that skin bunching significantly increased the skin-to-muscle distance in all subjects studied. In about 10% of subjects, this increase pushed the skin-to-muscle distance past 20 mm, which would mean a standard needle might not reach the muscle at all. Having a skin-to-deltoid distance of 20 mm or more was strongly correlated with a BMI of 30 or higher. This finding suggests that bunching is counterproductive in larger adults and could inadvertently turn what would have been a successful intramuscular injection into a subcutaneous one.
For lean individuals worried about bone contact, stretching the skin flat rather than bunching it, using a shorter needle, or injecting at a slight angle rather than a strict 90 degrees can all reduce the effective penetration depth. Clinical guidelines generally recommend inserting the needle at 90 degrees for standard IM injections, but this assumes average tissue thickness. Adjustments are warranted at the extremes of body composition.
Injections in Children and Infants
The risk of hitting bone is inherently higher in young children because they have less tissue depth everywhere. The anterolateral thigh is the preferred injection site for infants and toddlers because the deltoid muscle is too small to accommodate most injections at that age. But even the thigh has limited depth in a small child.
A randomized trial comparing injection techniques in infants and toddlers found that the WHO-recommended technique, which involves inserting the needle perpendicular to the skin surface without angling it relative to the femur, was the most reliable method for achieving intramuscular delivery. It resulted in fewer adverse reactions and was the easiest technique for clinicians to perform consistently. The key is using an appropriately short needle: 16 mm (5/8 inch) needles are standard for newborns, while 25 mm needles are reserved for older, larger children. Even a millimeter or two of extra needle length in a small infant can mean the difference between muscle and bone.
Parents sometimes worry about the needle appearing long relative to their child’s small arm or thigh. This concern is understandable, but pediatric needle lengths have been calibrated to tissue depth data. The greater practical risk in pediatric injections is actually that the child moves during the injection, causing the needle to shift position or go deeper than intended. Holding the child securely and stabilizing the injection site are as important as needle selection.
When Bone Contact Is More Likely Than You Would Expect
Certain populations have a higher risk of bone contact that is not always obvious at a glance. Elderly adults, even those who are not particularly thin, tend to have reduced muscle mass from age-related sarcopenia. The deltoid muscle thins with age, which means the distance from muscle surface to bone shrinks even if the overlying fat layer stays the same. A study examining injection safety in older adults specifically flagged this concern, noting that the ventrogluteal site was preferable partly because it maintained more protective tissue thickness in aging bodies.
People who are physically fit but have very low body fat, such as endurance athletes or bodybuilders during cutting phases, are another group at elevated risk. Their muscles may be well-developed, but the subcutaneous fat layer that would normally add a buffer of distance between the needle tip and bone is minimal. In these individuals, a standard 25 mm needle can reach bone at the deltoid, especially if the injection is given in the lateral portion of the muscle where it thins near the insertion point.
People receiving frequent intramuscular injections, such as those on long-term injectable medications, face cumulative tissue changes at commonly used sites. Repeated injections can cause localized fat loss (lipoatrophy) or scarring that thins the tissue over time, increasing the likelihood that a needle length that was once appropriate becomes too long for the site. Rotating injection sites is standard guidance partly for this reason.
Practical Advice for the Person Giving or Getting the Shot
If you are administering an IM injection, the most effective way to avoid hitting bone is to match needle length to the recipient’s body type. For an average-sized adult getting a deltoid injection, a 25 mm needle inserted at 90 degrees works well. For a thin adult or an older person with visible muscle wasting, consider a 16 mm needle or a shallower angle. For someone with a BMI over 30, a 38 mm (1.5 inch) needle may be necessary to reach muscle, and bone contact is unlikely because of the additional tissue depth.
If you are the one receiving the injection and you are concerned about bone contact, it helps to relax the muscle as much as possible. A tense deltoid is thinner and harder than a relaxed one, which can make the injection more painful if bone is contacted. Let your arm hang loosely at your side rather than tensing it. If you know you are particularly lean, it is reasonable to mention this to the person giving the injection. Most clinicians will not be offended by a brief conversation about needle length, and it may prompt them to use a shorter needle or adjust their technique.
For the person giving the injection, landmarking is critical. The injection should go into the thickest part of the deltoid, roughly two to three finger-widths below the acromion (the bony point of the shoulder). Injecting too high risks shoulder injury from the needle entering the bursa or joint capsule. Injecting too low puts the needle over a thinner part of the muscle where bone is closer to the surface. Getting the site right is at least as important as getting the needle length right.
How Self-Injectors Can Reduce Their Risk
A growing number of medications are now self-administered by intramuscular injection at home, from testosterone to certain biologics. Self-injectors face a unique challenge: they cannot easily see or assess their own injection site, particularly if using the deltoid on their non-dominant arm or the gluteal region. The anterolateral thigh is often the most practical site for self-injection because it is easy to see, access, and landmark.
For self-injectors, the thigh offers a larger target zone with generally thicker muscle than the deltoid, and the femur sits deeper beneath the surface than the humerus does in the upper arm. Bone contact is still possible in the thigh, particularly in very lean individuals, but the margin of error is wider. Using the middle third of the outer thigh, where muscle thickness peaks, provides the most reliable intramuscular delivery.
If you self-inject regularly, it is worth having your tissue depth assessed at least once, either by ultrasound or simply by having a clinician evaluate your injection sites and recommend appropriate needle lengths. What works for someone else with the same height and weight may not work for you, because body composition and fat distribution are highly individual. A small investment in getting this right upfront can save you from repeated painful bone contacts or ineffective subcutaneous deposits over months or years of treatment.